-
1.发明授权COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS 失效用于治疗与血管造影和/或血管生成有关的病症的化合物
公开(公告)号：EP0748219B8
公开(公告)日：2005-06-08
申请号：EP95910239.3
申请日：1995-02-09
IPC分类号： A61K31/24 , A61K31/42 , A61K31/275 , A61K31/415 , A61K31/495 , C07C211/45 , C07C255/01 , C07D209/18 , C07D231/38 , C07D241/36 , C07C255/41 , C07D239/93
CPC分类号： C07D487/04 , A61K31/235 , A61K31/275 , A61K31/277 , A61K31/38 , A61K31/40 , A61K31/415 , A61K31/42 , A61K31/495 , A61K31/502 , A61K31/505 , A61K31/517 , A61K31/535 , A61K38/00 , C07C229/60 , C07C255/36 , C07C255/40 , C07C255/41 , C07C255/66 , C07C317/46 , C07C327/44 , C07D209/18 , C07D239/93 , C07D239/94 , C07D241/42 , C07D241/44 , C07K14/71 , C07K16/2863 , C07K2319/32 , G01N33/5008 , G01N33/5011 , G01N33/502 , G01N33/5064 , G01N33/5091 , G01N33/6893 , G01N2333/71 , G01N2500/04
-
2.发明授权COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS 失效化合物与血管生成和/或血管相关疾病的治疗。
公开(公告)号：EP0748219B1
公开(公告)日：2005-04-06
申请号：EP95910239.3
申请日：1995-02-09
IPC分类号： A61K31/24 , A61K31/42 , A61K31/275 , A61K31/415 , A61K31/495 , C07C211/45 , C07C255/01 , C07D209/18 , C07D231/38 , C07D241/36 , C07C255/41 , C07D239/93
CPC分类号： C07D487/04 , A61K31/235 , A61K31/275 , A61K31/277 , A61K31/38 , A61K31/40 , A61K31/415 , A61K31/42 , A61K31/495 , A61K31/502 , A61K31/505 , A61K31/517 , A61K31/535 , A61K38/00 , C07C229/60 , C07C255/36 , C07C255/40 , C07C255/41 , C07C255/66 , C07C317/46 , C07C327/44 , C07D209/18 , C07D239/93 , C07D239/94 , C07D241/42 , C07D241/44 , C07K14/71 , C07K16/2863 , C07K2319/32 , G01N33/5008 , G01N33/5011 , G01N33/502 , G01N33/5064 , G01N33/5091 , G01N33/6893 , G01N2333/71 , G01N2500/04
摘要： The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction and particularly KDR/FLK-1 receptor signal transduction in order to regulate and/or modulate vasculogenesis and angiogenesis. The invention is based, in part, on the demonstration that KDR/FLK-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of FLK-1. These results indicate a major role for KDR/FLK-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express FLK-1 and the uses of expressed FLK-1 to evaluate and screen for drugs and analogs of VEGF involved in FLK-1 modulation by either agonist or antagonist activities is also described. The invention also relates to the use of the disclosed compounds in the treatment of disorders, including cancer, diabetes, hemangioma and Kaposi's sarcoma, which are related to vasculogenesis and angiogenesis.
-
3.发明公开COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS 失效为了与血管生成和/或血管处于连接疾病治疗的化合物。
公开(公告)号：EP0748219A1
公开(公告)日：1996-12-18
申请号：EP95910239.0
申请日：1995-02-09
IPC分类号： G01N33 , A61K31 , A61K38 , A61K39 , A61P1 , A61P3 , A61P9 , A61P11 , A61P13 , A61P15 , A61P17 , A61P27 , A61P35 , C07C229 , C07C255 , C07C317 , C07C327 , C07D209 , C07D231 , C07D239 , C07D241 , C07D261 , C07D333 , C07D403 , C07D487 , C07D491 , C07D498 , C07H21 , C07K14 , C07K16 , C12N5 , C12N15 , C12P21 , C12R1
CPC分类号： C07D487/04 , A61K31/235 , A61K31/275 , A61K31/277 , A61K31/38 , A61K31/40 , A61K31/415 , A61K31/42 , A61K31/495 , A61K31/502 , A61K31/505 , A61K31/517 , A61K31/535 , A61K38/00 , C07C229/60 , C07C255/36 , C07C255/40 , C07C255/41 , C07C255/66 , C07C317/46 , C07C327/44 , C07D209/18 , C07D239/93 , C07D239/94 , C07D241/42 , C07D241/44 , C07K14/71 , C07K16/2863 , C07K2319/32 , G01N33/5008 , G01N33/5011 , G01N33/502 , G01N33/5064 , G01N33/5091 , G01N33/6893 , G01N2333/71 , G01N2500/04
摘要： The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction and particularly KDR/FLK-1 receptor signal transduction in order to regulate and/or modulate vasculogenesis and angiogenesis. The invention is based, in part, on the demonstration that KDR/FLK-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of FLK-1. These results indicate a major role for KDR/FLK-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express FLK-1 and the uses of expressed FLK-1 to evaluate and screen for drugs and analogs of VEGF involved in FLK-1 modulation by either agonist or antagonist activities is also described. The invention also relates to the use of the disclosed compounds in the treatment of disorders, including cancer, diabetes, hemangioma and Kaposi's sarcoma, which are related to vasculogenesis and angiogenesis.
-
公开(公告)号：EP2528606A1
公开(公告)日：2012-12-05
申请号：EP11707712.3
申请日：2011-01-27
发明人： LEVITZKI, Alexander , SAGIV, Idit
IPC分类号： A61K31/517 , C07D239/94 , A61P11/06 , A61P11/08 , A61P17/06 , A61P37/00 , C07D401/12 , C07D403/12 , C07D405/12
CPC分类号： C07D239/94 , C07D401/12 , C07D403/12 , C07D405/12
摘要： Quinazoline derivatives are provided that specifically inhibit proliferation of T cells without affecting the level of IL-2 secreted from said T cells. These compounds as well as pharmaceutical composition comprising them are useful for the treatment of indications mediated by T cell proliferation.
-
5.发明授权RADIOLABELED IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY 有权表皮生长因子受体酪氨酸激酶和放射性注明不可逆抑制剂它们在放射性成像和放射治疗
公开(公告)号：EP1411993B1
公开(公告)日：2010-05-05
申请号：EP02702703.6
申请日：2002-03-12
申请人： YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM , HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
CPC分类号： A61K51/0459
-
6.发明公开RADIOLABELED ANILINOQUINAZOLINES AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY 审中-公开放射性注明苯胺基及其使用无线电操作和放射治疗
公开(公告)号：EP1673110A2
公开(公告)日：2006-06-28
申请号：EP04770505.8
申请日：2004-09-12
申请人： YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM , HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT CO., LTD.
IPC分类号： A61K51/04
CPC分类号： A61K51/0459 , A61K51/0463
摘要： Radiolabeled epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors and their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are disclosed.
-
7.发明公开USE OF BENZYLIDENE-MALONONITRILE DERIVATES FOR THE TREATMENT OF LEUKEMIA 失效使用亚苄基MALONONITRILDERIVATE用于治疗白血病
公开(公告)号：EP0754038A1
公开(公告)日：1997-01-22
申请号：EP95917619.0
申请日：1995-04-20
申请人： YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM , THE HOSPITAL FOR SICK CHILDREN RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP
发明人： LEVITZKI, Alexander , GAZIT, Aviv , ROIFMAN, Chaim
IPC分类号： A61K31
CPC分类号： A61K31/275
摘要： The present invention relates to products and methods useful for treating leukemia, in particular acute lymphoblastomic leukemias. Compounds described herein are effective in inhibiting activities associated with ALL both in vitro and in vivo. Methods for modifying such compounds and screening other compounds are also provided in order to identify additional compounds with similar or better inhibition properties.
-
公开(公告)号：EP1284734B1
公开(公告)日：2008-05-21
申请号：EP01938518.6
申请日：2001-05-30
IPC分类号： C07D217/02 , C07D401/12 , C07D405/12 , A61K31/472
CPC分类号： C07D401/12 , C07D217/02 , C07D405/12
摘要： Novel isoquinoline derivatives which are useful as inhibitors of protein kinases for experimental, medical, and drug design purposes are disclosed. Preferred compounds which are specific inhibitors of protein kinase B are also disclosed. Furthermore, pharmaceutical compositions comprising these protein kinase inhibitors, and methods of using such compositions for treatment and diagnosis of cancers, diabetes, cardiovascular pathologies, hemorrhagic shock, obesity, inflammatory diseases, diseases of the central nervous system, and autoimmune disease, are disclosed.
-
公开(公告)号：EP1161417A1
公开(公告)日：2001-12-12
申请号：EP00908883.2
申请日：2000-03-13
申请人： HSC Research and Development Limited Partnership , Yissum Research Development Company of the Hebrew University of Jerusalem
IPC分类号： C07C323/60 , C07D277/74 , A61K31/277 , A61K31/428 , A61P35/02
CPC分类号： C07D277/74 , C07C323/60
摘要： Compounds of general formula (I), wherein R1 is H or C1 to C3 alkyl; R2 is aryl or -(CH2)n-aryl and n is 1 to 4; R3 is H or CH3; and R4 is substituted or unsubstituted phenyl, pyridyl, thiophene, furan, indole, pyrrole, thiazole or imidazole are described, as well as methods for treating cell proliferative disorders and neoplastic disorders.
-
10.发明授权2-(2-PHENYLETHENYL)-1,3-BENZOTHIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER 有权2-（2-苯基乙烯基）-1,3-苯并噻嗪衍生物适宜癌症的治疗
公开(公告)号：EP2658847B1
公开(公告)日：2015-12-23
申请号：EP11813909.6
申请日：2011-12-27
IPC分类号： C07D279/08 , A61K31/5415 , A61P35/00
CPC分类号： C07D279/08 , A61K31/5415 , A61K45/06
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.025 秒)
